What are the Pros and Cons of autologous CAR T cell therapy? Summary slide from Georg Schett who also mentioned the exciting in vivo CAR approach using nanoparticules in myeloma, something to stay tuned for @RheumNow #APLAR25 https://t.co/kWjrx6N9Dv